United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $934,920.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $259.70, for a total value of $934,920.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $33,761. The transaction was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Stock Performance

UTHR opened at $266.22 on Wednesday. The firm has a market capitalization of $11.81 billion, a P/E ratio of 12.59 and a beta of 0.54. The stock’s 50 day moving average price is $238.38 and its two-hundred day moving average price is $229.88. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $266.65.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company’s revenue was up 33.7% on a year-over-year basis. During the same quarter last year, the firm posted $4.86 EPS. On average, equities analysts forecast that United Therapeutics Co. will post 23.88 earnings per share for the current year.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Rise Advisors LLC acquired a new stake in United Therapeutics in the 1st quarter valued at approximately $32,000. GAMMA Investing LLC acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $43,000. Benjamin F. Edwards & Company Inc. grew its holdings in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 117 shares in the last quarter. C M Bidwell & Associates Ltd. acquired a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $91,000. Finally, Janiczek Wealth Management LLC grew its holdings in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 84 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on UTHR. Wedbush reaffirmed an “outperform” rating and set a $308.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. The Goldman Sachs Group raised their price objective on United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Oppenheimer raised their price objective on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Wells Fargo & Company raised their price objective on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, May 2nd. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $308.78.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.